EUVIMEDEUVIMED entdecken
Crossref

Design and Synthesis of New Multi‐Target Coumarin Analogues Acting as Carbonic Anhydrases IX/XII and Topoisomerase II Inhibitors With Apoptotic Potential

Ahmed A Al-Karmalawy iD, Tarek A Yousef iD, Ali Khalil Ali iD, Mohamed A Zeidan, Marwa Sharaky, Arwa Omar Al Khatib iD, Hela Ferjani iD, Eslam M Abbass iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Ahmed A Al-Karmalawy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, The University of Mashreq, Baghdad, Iraq. Hauptthemen laut MEDLINE: Coumarins, Apoptosis, Topoisomerase II Inhibitors, Drug Design. Die Arbeit nennt 78 Literaturangaben. Gefördert von: This work was supported and funded by the Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU) (grant number IMSIU-DDRSP2501)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Through applying the hybridization technique, new coumarin derivatives ( 2–17 ) were prepared with substitution at coumarin C‐3 utilizing various heterocyclic derivatives, aiming to afford multi‐target carbonic anhydrases (CAs) IX/XII and topoisomerase II (Topo II) inhibitors with potent antiproliferative activity. Eight different cell lines were used to evaluate the growth inhibition percentages (GI%) of cancer cells determined by coumarin analogues 1–17 . Analogues 16 and 17 had the most substantial cytotoxic effects, achieving mean GI% of 86.59% and 85.74%, respectively, exceeding doxorubicin (Dox), which demonstrated a mean GI% of 69.15. Furthermore, the CAs IX/XII and Topo II inhibitory potentials for compound 17 were evaluated according to the protein expression analysis in the MG‐63 cancer cells. Analogue 17 downregulated the expression of CA IX, CA XII, and Topo II proteins by 0.43‐, 0.51‐, and 0.56‐fold change, respectively, indicating frontier inhibitory potentials. Additionally, analogue 17 achieved upregulation of apoptotic proteins (Caspases 3, 7, and 9, and BAX by 1.52‐, 3.10‐, 1.67‐, and 1.90‐fold change, respectively). On the contrary, compound 17 induced downregulation of the antiapoptotic proteins BCL‐2, MMP2, and MMP9 by 0.44‐, 0.38‐, and 0.45‐fold change, respectively. Besides, compound 17 achieved an arrest at the G0–G1 phase of the cell cycle and elevated the cellular levels from 65.75% of the control cells to 92.54%. Finally, three molecular docking processes of the superior analogue 17 toward CA IX, CA XII, and Topo II targets were performed to investigate its molecular interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CoumarinsApoptosisTopoisomerase II InhibitorsDrug DesignAntineoplastic AgentsCarbonic Anhydrase InhibitorsHumansStructure-Activity RelationshipDNA Topoisomerases, Type IICarbonic Anhydrase IXCell ProliferationCell Line, TumorMolecular StructureDrug Screening Assays, AntitumorDose-Response Relationship, DrugMolecular Docking SimulationCarbonic AnhydrasesAntigens, Neoplasm

Stichwörter der Autor:innen

apoptotic markerscarbonic anhydrasecoumarinmulti‐targettopoisomerase

Substanzen

CoumarinsTopoisomerase II InhibitorsDNA Topoisomerases, Type IICarbonic Anhydrase IXAntineoplastic Agentscarbonic anhydrase XIICarbonic Anhydrase InhibitorsCarbonic AnhydrasesCA9 protein, humanAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, College of Pharmacy, The University of Mashreq, Baghdad, Iraq.
  • College of Science, Chemistry Department, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
  • Chemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt.
  • Cancer Biology Department, Pharmacology Unit, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
  • Faculty of Pharmacy, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.

ORCID-Profile: Ahmed A Al-Karmalawy, Tarek A Yousef, Ali Khalil Ali, Arwa Omar Al Khatib, Hela Ferjani, Eslam M Abbass

Förderung

  • This work was supported and funded by the Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU) (grant number IMSIU-DDRSP2501).

Zitieren

APA

Al-Karmalawy, A. A., Yousef, T. A., Ali, A. K., Zeidan, M. A., Sharaky, M., Khatib, A. O. A., Ferjani, H., & Abbass, E. M. (2025). Design and Synthesis of New Multi‐Target Coumarin Analogues Acting as Carbonic Anhydrases IX/XII and Topoisomerase II Inhibitors With Apoptotic Potential. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70094

Vancouver

Al-Karmalawy AA, Yousef TA, Ali AK, Zeidan MA, Sharaky M, Khatib AOA, et al. Design and Synthesis of New Multi‐Target Coumarin Analogues Acting as Carbonic Anhydrases IX/XII and Topoisomerase II Inhibitors With Apoptotic Potential. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70094

BibTeX
@article{AlKarmalawy2025,
  author = {Al-Karmalawy, Ahmed A and Yousef, Tarek A and Ali, Ali Khalil and Zeidan, Mohamed A and Sharaky, Marwa and Khatib, Arwa Omar Al and Ferjani, Hela and Abbass, Eslam M},
  title = {Design and Synthesis of New Multi‐Target Coumarin Analogues Acting as Carbonic Anhydrases IX/XII and Topoisomerase II Inhibitors With Apoptotic Potential},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70094}
}
Kostenlos starten →